What was the primary end point observed in the RE-DUAL PCI study?
The primary end point observed in the RE-DUAL PCI study was major or clinically relevant nonmajor bleeding, with an incidence of 15.4% in the 110-mg dual-therapy group compared to 26.9% in the triple-therapy group (HR, 0.52; 95% CI, 0.42 to 0.63; P < .001 for noninferiority; P < .001 for superiority). The composite efficacy end point of thromboembolic events (MI, stroke, or systemic embolism), death, or unplanned revascularization was 13.7% in the 2 dual-therapy groups combined compared with 13.4% in the triple- therapy group (HR, 1.04; 95% CI, 0.84-1.29; P .005 for noninferiority). 